Charles Pitman CFA (Barclays) — Analyst Ratings, Accuracy & Track Record

Q: How accurate are Charles Pitman CFA's stock ratings?

About 50% of Charles's ratings were profitable over a one-year hold, with an average return of +1.6% per rating, measured by 13Foresight from historical prices.

Q: How is Charles ranked?

Charles Pitman CFA is ranked #1079 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

Analyst Tracker/Charles Pitman CFA

BARC

Charles Pitman CFA

Barclays

Wall Street Analyst

★★★☆☆

#1079

on 13Foresight · ranked by our own returns

50%

Success Rate

+1.6%

Average Return

2 of 4 calls profitable · -12.1% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compare To ⓘ

🔒 3-year track record is Pro. Showing 1-year — upgrade.

📈 Across the calls we could measure, roughly 50% of Charles Pitman CFA's ratings turned a profit when each position was held for 1 year — averaging +1.6% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

94 Buy 26 Hold 5 Sell

Charles's Stock Coverage 20 ratings · 2026-06-20

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	1-Yr Return
CH:PPGN PolyPeptide Group AG	Jun 16, 2026	BUY	Strong Buy -17.5% avg upside 3 analysts	$40.00	·
GB:0NZT UCB SA	Jun 12, 2026	HOLD	Buy -15.2% avg upside 19 analysts	$300.00	·
CH:BANB Bachem Holding AG	Jun 09, 2026	HOLD	Hold +28.0% avg upside 3 analysts	$70.00	·
DE:BAYN Bayer	May 19, 2026	BUY	Strong Buy +33.6% avg upside 28 analysts	$50.00	·
DE:MRK Merck KGaA	May 18, 2026	HOLD	Buy +2.2% avg upside 32 analysts	$130.00	·
CH:LONN Lonza Group Ltd	May 11, 2026	BUY	Strong Buy +26.0% avg upside 19 analysts	$670.00	·
DE:SRT3 Sartorius	Apr 23, 2026	BUY	Buy +27.9% avg upside 17 analysts	$270.00	·
FR:DIM Sartorius Stedim Biotech	Apr 23, 2026	BUY	Strong Buy +54.5% avg upside 10 analysts	$220.00	·
FR:BIM bioMerieux	Apr 23, 2026	HOLD	Buy +53.7% avg upside 12 analysts	$90.00	·
ES:GRF Grifols	Apr 22, 2026	BUY	Buy +64.4% avg upside 12 analysts	$12.50	·
CH:SDZ Sandoz Group Ltd	Mar 11, 2026	HOLD	Buy -7.8% avg upside 10 analysts	$75.00	·
IT:REC Recordati Industria Chimica e Farmaceutica SPA	Feb 12, 2026	HOLD	Hold -11.0% avg upside 6 analysts	$48.00	·
IT:DIA DiaSorin S.p.A.	Jan 06, 2026	SELL	Hold +58.9% avg upside 9 analysts	$60.00	·
GB:DIA Dialight	Jan 06, 2026	SELL	Strong Sell 1 analyst	—	·
BAYRY Bayer	Jan 06, 2026	BUY	Buy +293.9% avg upside 9 analysts	—	-5.8%
GB:0QW0 arGEN X	Oct 31, 2025	BUY	Strong Buy -24.9% avg upside 24 analysts	$850.00	·
FR:IPN Ipsen	Oct 24, 2025	HOLD	Buy -21.9% avg upside 17 analysts	$125.00	·
ARGX Argenx Se	Apr 28, 2025	BUY	Strong Buy -15.9% avg upside 46 analysts	$754.85	+24.8%
GRFS Grifols SA	Jan 04, 2024	BUY	Buy +247.6% avg upside 12 analysts	$20.90	-32.1%
ABBV AbbVie	Jan 13, 2022	BUY	Buy +2.9% avg upside 43 analysts	—	+19.4%

🔒 15 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Charles Pitman CFA — Frequently Asked Questions

How accurate are Charles Pitman CFA's stock ratings?

Based on the calls 13Foresight could measure, about 50% of Charles's ratings were profitable over a one-year hold, with an average return of +1.6% per rating, or -11.9% versus the S&P 500. We score every analyst the same way, from historical prices.

How is Charles ranked on 13Foresight?

Charles Pitman CFA is currently ranked #1079 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Charles cover?

Charles most recently has ratings on CH:PPGN, GB:0NZT, CH:BANB, DE:BAYN, DE:MRK, CH:LONN, DE:SRT3, FR:DIM, FR:BIM, ES:GRF, CH:SDZ, IT:REC and 8 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Rating Distribution

Welcome to 13Foresight!